Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy
Yang Gao, Naoe Taira Nihira, Xia Bu, et al.
Nature Cell Biology (2020) Vol. 22, Iss. 9, pp. 1064-1075
Open Access | Times Cited: 270

Showing 1-25 of 270 citing articles:

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Hirohito Yamaguchi, Jung-Mao Hsu, Wenhao Yang, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 5, pp. 287-305
Closed Access | Times Cited: 328
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Jinhua Liu, Zichao Chen, Yaqun Li, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 308
Programmed death ligand 1 signals in cancer cells
Anand Kornepati, Ratna K. Vadlamudi, Tyler J. Curiel
Nature reviews. Cancer (2022) Vol. 22, Iss. 3, pp. 174-189
Open Access | Times Cited: 262
Cancer Selective Target Degradation by Folate-Caged PROTACs
Jing Liu, He Chen, Yi Liu, et al.
Journal of the American Chemical Society (2021) Vol. 143, Iss. 19, pp. 7380-7387
Open Access | Times Cited: 196
Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade
Xiaoming Dai, Xia Bu, Yang Gao, et al.
Molecular Cell (2021) Vol. 81, Iss. 11, pp. 2317-2331.e6
Open Access | Times Cited: 153
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
Lars Ny, Henrik Jespersen, Joakim Karlsson, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 134
Emerging concepts in PD-1 checkpoint biology
Kristen E. Pauken, James A. Torchia, Apoorvi Chaudhri, et al.
Seminars in Immunology (2021) Vol. 52, pp. 101480-101480
Open Access | Times Cited: 132
Regulatory mechanisms of PD-1/PD-L1 in cancers
Xin Lin, Kuan Kang, Pan Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 96
USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy
Wenjun Xiong, Xueliang Gao, Tiantian Zhang, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 94
Protein acylation: mechanisms, biological functions and therapeutic targets
Shuang Shang, Jing Liu, Fang Hua
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 94
A Polymeric Hydrogel to Eliminate Programmed Death-Ligand 1 for Enhanced Tumor Radio-Immunotherapy
Wenhao Shen, Pei Pei, Chonghai Zhang, et al.
ACS Nano (2023) Vol. 17, Iss. 23, pp. 23998-24011
Closed Access | Times Cited: 94
Immune checkpoint inhibitor resistance in hepatocellular carcinoma
Zhijie Wang, Yichuan Wang, Peng Gao, et al.
Cancer Letters (2022) Vol. 555, pp. 216038-216038
Closed Access | Times Cited: 83
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
Holly K. Koblish, Liangxing Wu, Liang‐Chuan S. Wang, et al.
Cancer Discovery (2022) Vol. 12, Iss. 6, pp. 1482-1499
Open Access | Times Cited: 81
Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy
Shuangneng Yin, Zhaojun Chen, Dugang Chen, et al.
Theranostics (2023) Vol. 13, Iss. 5, pp. 1520-1544
Open Access | Times Cited: 62
Disrupting the phase separation of KAT8–IRF1 diminishes PD-L1 expression and promotes antitumor immunity
Yuanzhong Wu, Liwen Zhou, Yezi Zou, et al.
Nature Cancer (2023) Vol. 4, Iss. 3, pp. 382-400
Open Access | Times Cited: 58
Nuclear PD-L1 promotes EGR1-mediated angiogenesis and accelerates tumorigenesis
Jie Yu, Ai Zhuang, Xiang Gu, et al.
Cell Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 51
The complementarity of DDR, nucleic acids and anti-tumour immunity
Anand Kornepati, Cody M. Rogers, Patrick Sung, et al.
Nature (2023) Vol. 619, Iss. 7970, pp. 475-486
Closed Access | Times Cited: 46
The B7:CD28 family and friends: Unraveling coinhibitory interactions
Kelly P. Burke, Apoorvi Chaudhri, Gordon J. Freeman, et al.
Immunity (2024) Vol. 57, Iss. 2, pp. 223-244
Open Access | Times Cited: 30
Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
Sadique A. Javed, Asim Najmi, Waquar Ahsan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 27
CircPPAP2B controls metastasis of clear cell renal cell carcinoma via HNRNPC-dependent alternative splicing and targeting the miR-182-5p/CYP1B1 axis
Zaosong Zheng, Xiangbo Zeng, Yuanchao Zhu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 24
Advances in targeting histone deacetylase for treatment of solid tumors
Mu-Qi Shi, Ying Xu, Xin Fu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 23
The role of the immunosuppressive PD-1/PD-L1 checkpoint pathway in the aging process and age-related diseases
Antero Salminen
Journal of Molecular Medicine (2024) Vol. 102, Iss. 6, pp. 733-750
Open Access | Times Cited: 21
Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review
Aleksandra Golonko, Tomasz Pienkowski, Renata Świsłocka, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 4
Open Access | Times Cited: 18
A novel deacetylase inhibitor KLX suppresses liver fibrosis by deacetylating PPARγ through promoting ubiquitination-mediated HDAC1 degradation
Feng Zhang, Jinglun Song, Han Wu, et al.
Science China Life Sciences (2025)
Closed Access | Times Cited: 2
Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1
Dan Zhu, Ruidan Xu, Xinping Huang, et al.
Cell Death and Differentiation (2020) Vol. 28, Iss. 6, pp. 1773-1789
Open Access | Times Cited: 123
Page 1 - Next Page

Scroll to top